ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

Core Insights - ProFound Therapeutics has announced a four-year collaboration with Novartis to develop novel therapeutics for cardiovascular disease using its ProFoundry™ Platform [1][3] - The collaboration includes $25 million in upfront and near-term milestone payments, with potential downstream milestone payments of $750 million per target [1][3] Company Overview - ProFound Therapeutics focuses on discovering proteins within the expanded human proteome to develop first-in-class medicines for various diseases [4] - The ProFoundry™ Platform integrates multi-layered biological data and advanced computational tools to identify and validate novel proteins as drug targets [2][4] Collaboration Details - The partnership aims to leverage ProFound's capabilities in identifying novel proteins and Novartis' expertise in cardiovascular drug development [1][3] - The collaboration is expected to accelerate the discovery of new therapeutic targets and support the development of transformative therapies for cardiovascular diseases [3]